Navigation Links
Althea Technologies Appoints E.J. Brandreth to Vice President of Quality and Regulatory
Date:7/15/2008

e assisted in the development and launch of Zevalin(R) and Rituxan(R), CBER's first approved monoclonal antibody for cancer. Additionally, Mr. Brandreth has helped to develop two Parenteral Drug Association (PDA) technical reports.

E.J. Brandreth added, "I am very pleased to join the outstanding team of professionals here at Althea Technologies. I've watched the company's growth and I am really happy that I can call upon my experience to help assure the quality, compliance and facility validation efforts underway, which will best serve Althea's clients. I'm joining Althea as the activities focused upon the release of the newly constructed state-of-the-art commercial-scale facility head into high gear, so I will be able to jump right in as we write this exciting new chapter in the company's history."

About Althea Technologies, Inc.

Althea Technologies, a leading San Diego-based pharmaceutical services firm, provides critical manufacturing services that support researchers worldwide in their advancement of novel therapies and efforts to apply new genomic information. Althea's services include cGMP contract manufacturing of recombinant proteins, DNA-based therapeutics and vaccines, and aseptic filling. For more information, visit http://www.altheatech.com.


'/>"/>
SOURCE Althea Technologies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine news :

1. Planet Technologies Announces Agreement to Acquire Antigen Laboratories
2. Cardiovascular Technologies to be Highlighted at 5th Annual Cleveland Clinic Medical Innovation Summit, Oct. 1-3
3. VNUS Medical Technologies Announces Resignation of Chief Financial Officer and VP, Finance & Administration
4. Osteotech to Present at First Albany Capitals Regenerative Technologies Conference in New York
5. ReBuilder Medical Technologies, Inc. Reports International Sales Expansion
6. Advanced technologies aim to transform the coaching of top athletes
7. Global Med Technologies(R) Extends Its Worldwide Outreach
8. Acuo Technologies(R) Names Mike Dolan Vice President of Sales
9. ReBuilder Medical Technologies, Inc. Signs Agreement for Distribution in Maine
10. Neurobiological Technologies Reports Going Concern Qualification
11. MedCom USAs Subsidiary Card Activation Technologies, Inc.s SB2 Registration Declared Effective by SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)Rockville, MD "Why is it that men can be bastards and women must wear pearls and smile?" wrote author Lynn Hecht Schafran. The answer, according to an article in the Journal of Vision , may lie in
(Date:12/4/2009)Outcomes same whether procedure done immediately or 3 weeks later, study shows , , FRIDAY, Dec. 4 (HealthDay News) -- Timing of surgical repair or reconstruction of multiple-ligament knee inju
(Date:12/4/2009)Move a response to pressure from federal regulators to crack down on abuse of opioid medications , , FRIDAY, Dec. 4 (HealthDay News) -- The makers of 24 different prescription painkillers on F
(Date:12/4/2009)Dr. Redlener Applauds Historic Effort but Points out Potential Risk if America,s Safety Net Programs Are Lost in Final Health Care Reform ,, NEW YORK, Dec. 4 The New England Journal of Medicine
(Date:12/4/2009)Whether the H1N1 virus will come back during winter isn,t known, CDC says, , , FRIDAY, Dec. 4 (HealthDay News) -- The number of states reporting widespread swine flu activity continued to decl
Breaking Medicine News(10 mins):Health News:Are angry women more like men? 2Health News:Timing of Multiple-Ligament Knee Surgery May Not Matter 2Health News:Makers of Powerful Painkillers Present Safety Plans 2Health News:New England Journal of Medicine Perspective by Irwin Redlener, MD, Addresses Health Care Reform 2Health News:Swine Flu Continues to Wane 2
...2008) Patients with chronic hepatitis C (HCV) inf...according to a study published in Clinical Gastro...f the American Gastroenterological Association (AG...issue scarring. Additionally, patients with modera...
...low for testing of new drugs for vision-robbing di... -- The first animal model of age-related macular ... Clinic researchers. , This mouse model will help ...lindness in the elderly. , The researchers created...
... Members, Appoints New CEO -, BALTIMORE, Jan. 28 ...proving the healthcare of chronically ill seniors,...Patterson, has nominated five,new directors to the..., Patrick Hervy, who will remain on XLHealth,s bo...
...s a high probability that people who are prone to ...hat susceptibility through their genes, University...the Feb. 1 issue of The Journal of Infectious Dise...ility. The researchers further say they pinpointed...
...rant for Suicide Awareness Voices of,Education (SA...ployee with Cargill, earned the company,s Cargill ...rvice for his work as a volunteer with Suicide,Awa...to 100 employees and retirees internationally who ...
...ogical interventions for cancer patients do more t...prove health, new research suggests. , A study of...articipated in a psychological intervention progra... who exercised received a higher dose of their che...
Other Medicine News:Health News:Regular marijuana use increases risk of hepatitis C-related liver damage 2Health News:Regular marijuana use increases risk of hepatitis C-related liver damage 3Health News:Mouse Model of Age-Related Macular Degeneration Developed 2Health News:XLHealth Corporation Announces Executive Changes 2Health News:Study finds genetic link to human herpes susceptibility 2Health News:Study finds genetic link to human herpes susceptibility 3Health News:Volunteer for National Suicide Prevention Agency Earns Cargill Award 2Health News:Intervention program boosts health, reduces symptoms in breast cancer patients 2Health News:Intervention program boosts health, reduces symptoms in breast cancer patients 3
(Date:12/4/2009)TARRYTOWN, N.Y., Dec. 4 Bayer Diabetes Care today announced the three grand prize winners of Bayer,s "Express Your Simple Win Creativity Contest." Nick Jonas, of the Jonas Brothers, selected the winn
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
(Date:12/3/2009)ACTON, Mass., Dec. 3 Allen Medical Systems, a subsidiary of Hill-Rom Holdings, Inc. (NYSE: HRC ), today announced the launch of its new Allen Amatech(TM) OEM (Original Equipment Manufacturer) busin
Breaking Medicine Technology:Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 2Bayer 'Express Your Simple Win Creativity Contest' Grand Prize Winners Announced 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2Watching movies featuring characters who smoke negatively influences Mexican American teens 10968 1Watching movies featuring characters who smoke negatively influences Mexican American teens 10968 2Reportlinker Adds Renal Disease Treatments 3A Products and Therapies 62496 1Reportlinker Adds Renal Disease Treatments 3A Products and Therapies 62496 2Reportlinker Adds Renal Disease Treatments 3A Products and Therapies 62496 3Reportlinker Adds Renal Disease Treatments 3A Products and Therapies 62496 4Reportlinker Adds Renal Disease Treatments 3A Products and Therapies 62496 5Reportlinker Adds Renal Disease Treatments 3A Products and Therapies 62496 6Reportlinker Adds Renal Disease Treatments 3A Products and Therapies 62496 7Reportlinker Adds Renal Disease Treatments 3A Products and Therapies 62496 8Reportlinker Adds Renal Disease Treatments 3A Products and Therapies 62496 9Reportlinker Adds Renal Disease Treatments 3A Products and Therapies 62496 10Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies 3A Global Markets 62492 1Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies 3A Global Markets 62492 2Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies 3A Global Markets 62492 3Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies 3A Global Markets 62492 4Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies 3A Global Markets 62492 5Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies 3A Global Markets 62492 6Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies 3A Global Markets 62492 7Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies 3A Global Markets 62492 8Reportlinker Adds Antibiotic Resistance and Antibiotic Technologies 3A Global Markets 62492 9
...ical Significance, FRAZER, Pa., May 01, 2007 /PR...clinical trial presented today at the 59th Annual,...Boston highlights,data demonstrating that FENTOR...al for the treatment of breakthrough pain in patie... opioids around-the,clock to manage their persis...
...- Genentech, Inc. (NYSE:DNA),and Biogen Idec, Inc.... Phase II clinical study of Rituxan(R) (rituximab)...erosis (RRMS) were,presented today at the American...n. Rituxan is a therapeutic antibody that targets ...There remains a great need for safe and effective ...
Other Medicine Technology:Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 2Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 3Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 4Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 5Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 6Cephalon Presents Positive Results for Fentora in Breakthrough Pain,Associated with Neuropathic Conditions 7Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 2Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 3Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 4Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 5Rituxan Phase II Data in Patients with Relapsing-Remitting Multiple,Sclerosis Presented at the American Academy of Neurology 6
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
...ational reference laboratory and a worldwide leade...t. ARUP offers an extensive test menu of highly co...tomic pathology. Owned by the University of Utah, ...of the nation's university teaching hospitals and ...
Medicine Products: